anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To compare obstetrical and neonatal outcomes of embryo transfer cycles using fresh vs. frozen-thawed testicular sperm derived from microTESE in non-obstructive azoospermia (NOA) patients.
DESIGN: The retrospective cohort study included a total of 48 couples diagnosed with NOA who underwent 93 ET cycles, both fresh and frozen-thawed embryos, and resulted in pregnancy. ET cycles were divided into two groups according to sperm type, fresh (46 cycles, 49.5%) or frozen (47 cycles, 50.5%) testicular sperm. The primary outcome was the birth weight of newborns correlated with gestational week (birth weight percentile).
RESULTS: A comparison of patients' basic characteristics and ET cycle parameters showed no significant clinical differences between the groups. A total of 172 embryos were transferred, 86 (50%) in each group. A higher rate of good-quality blastocysts was found in the fresh testicular group (83.3% vs. 50%, p = 0.046). A comparison of pregnancy outcomes showed no significant differences in clinical pregnancy, implantation, or live birth rates. A total of 53 cycles resulted in live birth, 26 (49%) and 27 (51%) in the fresh and frozen groups, respectively. No difference was found in pregnancy length, delivery mode, or obstetrical complications. A total of 61 newborns were included, 31 (51%) and 30 (49%) in fresh and frozen testicular groups, respectively. No significant differences were found in mean birth weight or birth weight percentile between the groups.
CONCLUSION: No significant differences were found in obstetrical outcomes when comparing ET cycles using fresh or frozen-thawed testicular sperm retrieved from microTESE. Moreover, there is no association between the sperm source and the birth weight of newborns.
The present invention relates to compounds that can specifically activate TLR7. The compounds of the invention are useful because they can stimulate innate immunity. The compounds of the invention can be used in the treatment of conditions including cancer, viral infections and skin lesions. The compounds can optionally be formulated for enhanced penetration following topical administration, said composition preferably initiating a local specific inflammatory cytokine response while limiting undesirable erythema and other inflammatory reactions. The invention also relates to pharmaceutical compositions comprising the compound of the invention and preferably an additional compound such as imiquimod and/or resiquimod (R848). The invention also relates to a composition comprising a compound of the invention and to a compound for use as a medicament. Other aspects, embodiments, advantages and applications of the invention will become clear from the further description herein.
Rhinogenic headache (RH), arising from nasal and sinus pathologies, present a diagnostic challenge due to their diverse etiologies. This study investigates a unique case where RH coincides with infraorbital nerve dehiscence, delving into the intricate relationship between sinonasal anatomy and neurovascular complications. The infraorbital nerve contacted a cyst in the maxillary sinus. Centripetal endoscopic sinus surgery was performed to open the maxillary sinus and remove the cyst. After 3 months of follow-up, the patient had a notable improvement in symptoms with a reduced headache. This case highlights the significance of considering uncommon anatomic variations, such as infraorbital nerve dehiscence, within the context of RH. Diligent history-taking and appropriate use of radiologic investigations are pivotal for guiding clinicians toward an accurate diagnosis and determining the most appropriate course of treatment.
The US Dietary Guidelines for Americans recommends that individuals consume approximately 2-4 c of vegetables each day to reduce risk of chronic disease, but current methods for assessing intake are either inaccurate (self-report) or invasive (blood carotenoid levels). Recent research indicates that skin carotenoid status may be a useful biomarker of vegetable intake, but the sensitivity to dose in unknown. In this study, we propose to test the dose-response of skin carotenoids to consumption of 3 different levels of vegetable juice (with a control group receiving water). We will test skin carotenoids in two ways: using resonance Raman spectroscopy (RRS), which we have previously validated, and with a new technique, pressure mediated reflection spectroscopy (RS; the "Veggie Meter"). We will compare the two techniques during an 8-week provided tomato-based juice intervention. Skin carotenoid readings will be compared to blood carotenoid concentrations and single nucleotide polymorphisms (SNPs) of genes related to the uptake, transport, and metabolism of carotenoids will be examined in blood and saliva.
This will be a first in human, open-label, adaptive clinical trial investigating the oral exposure of toxigenic C. difficile in healthy volunteers. The trial will consist of at least one cohort (cohort A), with an option to escalate to a second (cohort B) and third cohort (cohort C) if needed. In every cohort volunteers will be exposed for 12 consecutive days (D0-D11) to once a day a capsule with 10\^4 CFU toxigenic C. difficile spores. Escalation will be done by adding antibiotic pretreatment (vancomycin in cohort B and clindamycin in cohort C) the five days before C. difficile exposure (D-6 - D-1). Escalation will be based upon safety first and secondly upon microbiological and clinical endpoints (ideally aiming for a 70% attack rate in both). In every cohort there will be first a pilot group of 5 volunteers, after which there is an option to include a confirmatory group of 15 more participants in the same cohort if the exposure is safe and the threshold for the microbiological and clinical endpoint is met.

Immediately following the first ingestion of the C. difficile spores (day 0), volunteers will be closely and strictly monitored for adverse events (AEs) and vital signs in an outpatient setting. Until day 35, AEs, vital signs and stool samples for C. difficile toxin PCR/EIA, culture, and microbiota analysis will be collected every other day, safety laboratory measurements will be performed once in four days (starting from day 0). Immunology samples will be collected on day 0, 2, 20, 35 and 84. If a volunteer develops symptoms of CDI the volunteer needs to visit the research clinic the same day for a physical check-up, and collection of a blood and stool sample, and, if needed (antibiotic) treatment will be started according to standard of care. Any recurrent episode of a C. difficile infection will be treated with fecal microbiota transplantation (FMT). A final visit will take place after three months (day 84), with collection of feces and blood. If a volunteer is still C. difficile positive at this timepoint, they will be followed every three months until decolonisation is reached, up to a maximum of one year after the start of the trial. Decolonisation will be de-fined as having a negative molecular C. difficile test on at least two different timepoints.
In this project, we will leverage on a locally developed electroencephalograph (EEG)-based BCI technology for decoding affective states of the brain, and thereby develop a closed-loop sensing and stimulation mechanism. The technology uses advanced neural signal computing on the EEG in real-time and audio feedback using a machine learning model that associates individual user's EEG characteristics in relation to music-emotion features. The system is portable and will allow emotion regulation training to be done outside of hospital setting with ease thus potentially addressing the treatment gap for MDD in the elderly.

This is a two group randomized study. One group will undergo the intervention which is 24 sessions of BCI emotion regulation training (i.e. listening to music with audio feedback to regulate emotions towards positive affect) over an 8-week period. The control group will undergo 8 weeks of music sessions, without any emotion regulation training. Both groups will undergo pre- and post- psychometric assessments looking at cognition, quality of life, functioning and emotional states. This study will also carry out functional MRI of the brain before and after 8 weeks of either training (intervention) or music music session (control) to examine changes associated with the affective BCI training. Study findings derived from psychometric assessments, EEG analysis and neuroimaging will provide evidences on efficacy and usability of this technology.
Chronic tinnitus is a symptom of disturbed auditory perception. More than 90% of tinnitus patients suffer from hearing loss. Many people experience tinnitus and seek for treatment, but suffering and actual burden of tinnitus is individually very different, sometimes it disappears after a certain time even without treatment. This process is called habituation. The actual suffering from tinnitus depends on stress symptoms and other psychosomatic comorbidities like depression, anxiety and sleeping disorders.Up-to-date there is no therapy that can completely switch off tinnitus, mainly because the origin and expression of tinnitus are individual and very different. This educational publication summarizes and evaluates scientific therapeutic approaches for chronic tinnitus, based on the newly elaborated S3-Guideline "Chronic Tinnitus", under the lead management of the German Society of ENT, Head and Neck-Surgery, published in 2021. It focusses on recommendations for counselling, interventions against hearing loss and psychotherapy, mainly cognitive behavioural therapy.
Azithromycin tablets, USP 250 mg are supplied as white, oblong, biconvex, film-coated tablets containing azithromycin dihydrate, USP equivalent to 250 mg of azithromycin. Azithromycin tablets, USP 250 mg are debossed with “250” on one side. These are packaged in bottles and blister cards of 6 tablets.

Azithromycin tablets, USP 500 mg are supplied as white, oblong, biconvex, film-coated tablets containing azithromycin dihydrate, USP equivalent to 500 mg of azithromycin. Azithromycin tablets, USP 500 mg are debossed with “500” on one side. These are packaged in bottles and blister cards of 3 tablets.
This Phase 1/2 Randomized, Placebo Controlled, Double-Blind clinical trial will evaluate the safety, tolerability, and pharmacodynamics of ANZ-521, an investigational product that is a weakened form (attenuated) of Listeria monocytogenes, a type of bacteria that is commonly found in the environment. ANZ-521 has been altered in the lab to reduce its ability to cause disease, while maintaining stimulation of the immune system. ANZ-521 has also been genetically modified with recombinant DNA to encode consensus sequence antigens called NS5B polymerase and NS3 proteinase that correspond to viral proteins found on the virus causing Hepatitis C. It is hoped that ANZ-521 will stimulate an immune response to the Hepatitis C virus (HCV) in the liver, thereby demonstrating an effective therapy for individuals with chronic HCV infection.

The purpose of this first clinical trial with ANZ-521 is to identify an appropriate dose of the investigational agent for later clinical studies and to explore safety when given to consenting adults with HCV. Immunological response to ANZ-521 in study participants will also be measured. Patients who choose to enter the study must meet all study entry criteria. The first part of the study (Part A) will enroll subjects who have received prior treatment with standard of care therapy for HCV. The second part of the study (Part B) will enroll subjects who have not previously received standard of care therapy for HCV or were intolerant to standard of care. Qualifying study patients will be assigned to receive one of at least 2 dose levels of ANZ-521 or placebo. Each patient may receive up to 3 intravenous administrations (28 days apart) of ANZ-521 or placebo at their assigned dose level.
Bosentan is not effective in the treatment of congestive heart failure with left ventricular dysfunction. In a pair of studies, 1613 subjects with NYHA Class III-IV heart failure, left ventricular ejection fraction <35%, on diuretics, ACE inhibitor, and other therapies, were randomized to placebo or bosentan (62.5 mg twice daily titrated as tolerated to 125 mg twice daily) and followed for up to 70 weeks. Use of bosentan was associated with no benefit on patient global assessment (the primary end point) or mortality. However, hospitalizations for heart failure were more common during the first 4 to 8 weeks after bosentan was initiated. In a placebo-controlled trial of patients with severe chronic heart failure, there was an increased incidence of hospitalization for CHF associated with weight gain and increased leg edema during the first 4 to 8 weeks of treatment with bosentan. Patients required intervention with a diuretic, fluid management, or hospitalization for decompensating heart failure.
* Thiazolidinediones, including ACTOS, cause or exacerbate congestive heart failure in some patients (see WARNINGS). After initiation of ACTOS, and after dose increases, observe patients carefully for signs and symptoms of heart failure (including excessive, rapid weight gain, dyspnea, and/or edema). If these signs and symptoms develop, the heart failure should be managed according to the current standards of care. Furthermore, discontinuation or dose reduction of ACTOS must be considered.   

  * ACTOS is not recommended in patients with symptomatic heart failure. Initiation of ACTOS in patients with established NYHA Class III or IV heart failure is contraindicated (see CONTRAINDICATIONS and WARNINGS).
The invention relates to a medicament for treating pulmonary tuberculosis by combined chemotherapy with traditional Chinese medicine Fuying and a preparation method; in the medicament, a traditional Chinese medicine of Fuying No. I comprises gecko, donkey-hide gelatin, stemona, adenophora stricta, radix ophiopogonis, prunella vulgaris, radix scrophulariae, fritillaria thun-bergli, cortex lycii radicis, bletilla striata, picrorhiza scrophulariiflora pennell, rehmanniae radix, and anemarrhena, and is mainly used for expelling evil and nourishing yang; a traditional Chinese medicine of Fuying No. II comprises codonopsis pilosula, Chinese yam, poria cocos, schisandra chinensis, radix rehmanniae preparata, angelica, caulis spatholobi, gentrin knotweed, bighead atractylodes rhizome, and radix astragali, and is mainly used for strengthening the body resistance and nourishing body; western medicines participating the combined chemotherapy comprise: streptomycin injections, isoniazid tablets, rifampin, and pyrazinamide capsules; during the combined chemotherapy with the medicines, not only stable therapeutic effect on pulmonary tuberculosis is realized, but also nourishing treatment effect on patients with hepatopathy is realized; during preparation, geckoes are grinded into fine powder, and fried with donkey-hide gelatin; then the other medicines are cleaned, dried, pulverized, and grinded into fine powder; the fine powder is sieved by a No. 6 sieve to obtain a pulvis; the pulvis is packaged into bags to obtain the Fuying No. I. During the preparation of the Fuying No. II, the medicines are also selected, cleaned, pulverized, and grinded into fine powder; the fine powder is sieved by a No. 6 sieve to obtain a pulvis; the pulvis is packaged into bags to obtain the Fuying No. II. During treatment, the traditional Chinese medicine Fuying is combined with western medicines for administration.
The invention relates to a traditional Chinese medicine preparation for treating hypertension and a preparation method thereof. The traditional Chinese medicine for treating hypertension is composed of rauvolfia verticillate, physochlaina macrophylla, harlequin glorybower, prunella vulgaris, scutellaria baicalensis, radix scrophulariae, fructus crataegi, arabic cowry shell, apocynum venetum, ,angnolia officinalis, fried eucommia ulmoides, poria cocos and motherwort fruit. The raw materials are prepared into tablets, granules, capsules or other pharmaceutically-acceptable dosage forms according to specific processes. The traditional Chinese medicine preparation for treating hypertension has the effect of clearing heat, soothing the nerves and reducing blood pressure and is mainly used for treating primary hypertension. According to a pharmacodynamic test, the traditional Chinese medicine preparation for treating hypertension has obvious effect of lowering blood pressure. The invention further discloses the preparation method of the traditional Chinese medicine preparation for treating hypertension.
Group D Diclofenac diethylammonium 1% spray (Painout Ice 1%-Ankara) was applied to the painful area from a distance of approximately 10-15 cm in a maximum of 6 puffs. Each puff contained 5.8 mg diclofenac diethylammonium.
Asciminib is a first-in-class allosteric inhibitor of the kinase activity of BCR::ABL1, specifically targeting the ABL myristoyl pocket (STAMP). This review focuses on the pharmacokinetic (PK) and pharmacodynamic data of asciminib, which is approved at a total daily dose of 80 mg for the treatment of adult patients with chronic myeloid leukemia in chronic phase who are either resistant or intolerant to ≥ 2 tyrosine kinase inhibitors or those harboring the T315I mutation (at a dose of 200 mg twice daily). Asciminib is predicted to be almost completely absorbed from the gut, with an absolute bioavailability (F) of approximately 73%. It should be administered in a fasted state, as food (particularly high-fat meals) reduces exposure. Asciminib displays a slightly greater than dose-proportional increase in exposure, with no time-dependent changes in PK observed following repeated dosing. This drug shows low clearance (6.31 L/h), with a moderate volume of distribution (111 L) and high human plasma protein binding (97.3%). The apparent terminal elimination half-life (t1/2) across studies was estimated to be between 7 and 15 h. The PK of asciminib is not substantially affected by body weight, age, gender, race, or renal or hepatic impairment. Asciminib is primarily metabolized via CYP3A4-mediated oxidation (36.0%) and UGT2B7- and UGT2B17-mediated glucuronidation (13.3% and 7.8%, respectively); biliary secretion via breast cancer resistance protein contributes to about 31.1% to total systemic clearance, which is mainly through hepatic metabolism and biliary secretion through the fecal pathway, with renal excretion playing a minor role. The potential for PK drug interaction for asciminib both as a victim and a perpetrator has been summarized here based on clinical and predicted drug-drug interaction studies. Robust exposure-response models characterized asciminib exposure-efficacy and exposure-safety relationships. In patients without the T315I mutation, the exposure-efficacy analysis of the time course of BCR::ABL1IS percentages highlighted the existence of a slightly positive, albeit not clinically significant, relationship. Higher exposure was required for efficacy in patients harboring the T315I mutation compared with those who did not. The exposure-safety relationship analysis showed no apparent association between exposure and adverse events of interest over the broad range of exposure or dose levels investigated. Asciminib has also been shown to have no clinically relevant effect on cardiac repolarization. Here, we review the clinical pharmacology data available to date for asciminib that supported its clinical development program and regulatory applications.
The present invention discloses a frozen dry bamboo leaf flavone powder injection, particularly a novel dosage form with rapid absorption and stable quality. The powder injection contains 25 to 95 wt% of bamboo leaf flavone, 5 to 72 wt% of filling agent and smaller than 5 wt% of water. The present invention also discloses a method for preparing the frozen dry bamboo leaf flavone powder injection. The method is suitable for large-scale industrialized production. The present invention also discloses a tool for the frozen dry bamboo leaf flavone powder injection. The injection has the functions for increasing coronary blood flow, alleviating myocardial ischemia, alleviating platelet aggregation, resisting myocardial infarction, alleviating cerebral ischemia, etc.
A cosmetic product is provided packaged in a dispenser with separate first and second storage areas. The first of the areas contains a first cosmetic composition containing a first dermal active agent, preferably selected from keratolytic skin agents. Particularly preferred are alpha- and beta-hydroxy carboxylic acids as first dermal active placed in a composition having a pH from about 1 to about 5.5. The second area contains a second cosmetic composition with a second dermal agent incompatible with the first composition. Particularly preferred second dermal agents are retinoids, vitamins, enzymes and anti-oxidants. Most preferred is retinol. The dispenser allows transfer of the first and second compositions through an exit nozzle in a respective dispensing weight ratio of from about 30:1 to about 2:1.
The invention relates to a preparation method and use of Xanthoceras sobifoba kernel oil extracted from supercritical fluid and a preparation of the Xanthoceras sobifoba kernel oil. The preparation method comprises the steps of grinding Xanthoceras sobifoba kernels, sieving by virtue of a 10-100-mesh sieve, and carrying out supercritical fluid extraction in an extraction kettle, so as to obtain the Xanthoceras sobifoba kernel oil and a kernel residue rich in proteins, wherein the kernel residue can be used for extracting total saponins and has an extremely high medical value. Compared with a traditional squeezing process, a CO2 supercritical fluid extraction method has the advantages that the process is simple, the production cycle is short, the extraction efficiency is high, and the serious damage of unsaturated fatty acid in grease and the denaturationof the proteins in medicine residues at the high temperature are avoided. Compared with a method for extracting by virtue of organic solvents such as petroleum ether, the CO2 supercritical fluid extraction method has the advantages that the residual solvent is avoided, operation condition are mild, and the production is safe, toxic free and environmentally friendly. The oil extraction rate of the Xanthoceras sobifoba kernels is not lower than 50%, and GC-MS detection shows that the content of unsaturated fatty acid reaches up to 75% or above. By adding medical auxiliary materials, the dose forms of soft capsules, micro-capsules, cyclodextrin coated preparations, dripping pills and the like can be prepared and can be used for developing health products for preventing and treating hypertension, hyperlipemia and diseases of cardiovascular systems.